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There are still debates regarding the appropriate primary treatment policy for asymptomatic primary colorectal lesions in 
cases of unresectable metastatic colorectal cancer. Even though there are patients with asymptomatic primary tumors 
when starting chemotherapy, those patients may still undergo surgery due to complications related to primary tumors in 
the middle of chemotherapy; therefore, controversy exists regarding surgical resection of primary colorectal lesions in 
cases where symptoms are absent when making a diagnosis. Thus, based on the published literature, we discuss opinions 
that prefer first-line surgery for primary tumors as well as opinions favoring first-line chemotherapy for treating unresect-
able synchronous metastatic colorectal cancer. Although the upfront chemotherapy including targeted agents is suggested 
as an effective treatment in recent years, the first line surgery has been a preferred treatment for decades. The first line sur-
gery is beneficial to prolong the survival duration given the retrospective analysis of randomized trial data. So far, no pro-
spective comparison study has only focused on the first-line treatment modality; thus, future clinical studies focusing on 
the survival duration and the quality of life should be performed as soon as possible. Furthermore, at this point, multidis-
ciplinary team approaches would be helpful in finding the appropriate therapy. Regardless of symptoms, the performance 
status and the tumor burden should be taken into consideration as well. In case of surgical resection, minimally invasive 
surgery, such as laparoscopic surgery, is recommended. 
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Metastatic colorectal cancer (mCRC) is TNM stage IV cancer, 
and approximately 20% to 25% of colorectal cancer patients have 
distant metastasis at their initial diagnosis; also, metastasis is 
known to occur in about 50% of patients eventually. So far, 
colorectal cancer treatment has been primarily based on surgery. 
Radiation and chemotherapy have been used as adjuvant treat-
ment to reduce the risk of metastasis and recurrence [3]. There-
fore, the first step is to decide on resections of the primary tumor, 
as well as distant metastases, in patients with synchronous mCRC. 
In cases where the resection of a distant metastasis is not possible, 
either the primary tumor resection will be performed first, fol-
lowed by chemotherapy or chemotherapy will be performed first. 
If patients present with clinical symptoms involving in primary 
tumors, such as severe bleeding, obstruction, perforation, and 
pain, the primary tumors should be removed. 
Debates are still ongoing regarding the appropriate primary 
treatment policy for asymptomatic primary colorectal lesions in 
unresectable mCRC. Even though there are patients with asymp-
tomatic primary tumors when starting chemotherapy, surgery 
may still be performed due to primary-tumor-related complica-
INTRODUCTION
Colorectal cancer is the third most common cancer after lung 
cancer and breast cancer worldwide; according to the report by 
World Health Organization (WHO), there were 1,160,000 newly-
diagnosed patients in 2007, which was 9.4% of total cancer occur-
rence [1]. In Korea, colorectal cancer was found to be the third 
most common cancer after thyroid cancer and gastric cancer, and 
in 2009, there were 24,986 new patients and 7,051 patients who 
died due to colorectal cancer [2].
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tions in the midst of chemotherapy; therefore, controversy exists 
regarding surgical removal of primary colorectal lesions in the ab-
sence of symptoms when making a diagnosis.
According to the guidelines provided by the National Compre-
hensive Cancer Network, resection of a primary tumor is recom-
mended only if patients present with symptoms such as obstruc-
tion, bleeding, and perforation while combination chemotherapy 
is suggested if there are no symptoms [4]. In spite of this, tradi-
tionally, the removal of the primary tumor has been favored, and 
in United States (US), 17,658 out of 26,754 patients (66%) with 
mCRC between 1998 and 2000 underwent resections for primary 
tumors based on the data from Surveillance, Epidemiology, and 
End Results (SEER) [5].
Justifications for a preference to resect asymptomatic primary 
tumors are a potentially better survival rate expected and fewer 
complications and mortalities after surgery as emergent surgery 
can be avoided [6-10]. Furthermore, potential side effects, such as 
weight loss, pain, malnutrition due to obstruction, an anemia 
caused by bleeding, can be prevented [11], and tumor staging is 
more accurate as metastatic lesions are confirmed in the abdomi-
nal cavity when performing a palliative resection, which is an ad-
ditional benefit of resecting of primary tumors [12]. Lowering the 
tumor burden maximizes the benefit of chemotherapy and in-
creases the potential for surgery with a curative intent [7].
On the other hand, some may not prefer the resection of the pri-
mary tumor because it is not clear that a resection of the primary 
tumor will improve the survival rate and the quality of life [13-15] 
and because there have been no appropriate comparison studies 
through randomized studies [16, 17]. In addition, the association 
between the resection of the primary tumors and an improved 
survival rate should be further investigated because of the advances 
in chemotherapies for colorectal cancer via the introduction of tar-
geted agents (e.g., bevacizumab and cetuximab) in the mid-2000s 
and of a new generation of cytotoxic agents (e.g., irinotecan and 
oxaliplatin), in addition to 5-fluorouracil (5-FU). Thus, the authors 
discussed in regard to opinions that preferred first line surgery for 
primary tumor as well as opinions favored the first line chemo-
therapy in unresectable synchronous mCRC based on the pub-
lished literature and introduced clinical studies currently ongoing 
(Table 1). 
TREATMENT STRATEGIES FOR 
SYNCHRONOUS METASTATIC COLORECTAL 
CANCER
Multidisciplinary team discussion is critical to determine the ap-
propriate treatments for mCRC. In stage IV colorectal cancer, 
there are not many cases in which a curative resection of the pri-
mary tumor and metastatic lesions (e.g., liver, lung, and distant 
lymph-node metastases or peritoneal metastases) is selected at the 
first diagnosis. However, complete recovery is possible if resect-
able metastatic lesions and the primary colorectal cancer are en-
tirely removed from the patients; thus, determining appropriate 
patients for either surgery or chemotherapy is very important. 
Resectability of mCRC can be classified into resectable meta-
static group, potentially resectable, and unresectable metastatic 
group. In patients with synchronous mCRC, there are a number 
of options for surgery and chemotherapies (radiation therapy), 
depending upon the location of the primary tumors (either colon 
or rectum) and the progress of tumor metastasis. Resectability 
should be determined by multidisciplinary team approaches via 
comprehensive discussion between colorectal surgeons, hepato-
Table 1. Summary of study characteristics
Characteristic Investigator Year of publication Study period Study design Primary tumor
Favoring resection Ruo et al. [10] 2003 1996–1999 Retrospective single center study Colon & rectum
Galizia et al. [7] 2008 1995–2005 Retrospective single center study (case-matched) Colon & rectum
Kaufman et al. [18] 2008 1998–2003 Retrospective single center study Colon & rectum
Bajwa et al. [19] 2009 1999–2005 Retrospective single center study Colon & rectum
Venderbosch et al. [22] 2011 2003–2004 Retrospective analysis of randomized trials (CAIRO) Colon & rectum
2005–2006 Retrospective analysis of randomized trials (CAIRO2) Colon & rectum
Karoui et al. [20] 2011 1998–2007 Retrospective multicenter study Colon
Ferrand et al. [23] 2013 1997–2001 Retrospective analysis of randomized trials (FFCD 9601) Colon & rectum
Favoring nonresection Scoggins et al. [44] 1999 1985–1997 Retrospective single center study Colon & rectum
Tebbutt et al. [43] 2003 1990–2000 Retrospective single center study Colon & rectum
Michel et al. [9] 2004 1996–1999 Retrospective single center study Colon & rectum
Benoist et al. [12] 2005 1997–2002 Retrospective single center study (case-matched) Colon & rectum
Seo et al. [52] 2010 2001–2008 Retrospective single center study Colon & rectum
McCahill et al. [53] 2012 2006–2009 Prospective, multicenter phase II trial Colon
CAIRO, CApecitabine, IRinotecan, and Oxaliplatin; FFCD, Fédération Francophone de Cancérologie Digestive.
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biliary surgeons, urologists, gynecologists, and thoracic surgeons. 
Although patients may not be candidates for a resection on the 
first diagnosis, later they may be reclassified into the potentially 
resectable group or the resectable metastatic group after combina-
tion chemotherapy. Such cases would be identified as the poten-
tially resectable metastatic group, and chemotherapy including 
targeted agents would be recommended from the first diagnosis. 
If removing the primary and metastatic lesions is considered im-
possible owing to multiple metastases, treatment strategies would 
be established for palliative chemotherapy to extend survival du-
ration, improve symptoms, and maintain the quality of life.
Traditionally, the objective for unresectable colorectal cancer 
treatment has been to prolong the survival duration and improve 
the quality of life, but since the 2000s, the outcome of treatment 
has improved, new anticancer drugs have been developed, ad-
vances in combination chemotherapy and operation techniques 
have been made, and multidisciplinary team discussions have 
been emphasized. Thus, selection of an appropriate treatment ap-
proach and the establishment of proper objectives for the therapy 
(e.g., survival duration extension, complete cancer cure, improve-
ment of cancer-related symptoms, or maintenance of the quality 
of life) have become more significant. 
THE OPINION IN FAVOR OF FIRST-LINE 
SURGERY IN UNRESECTABLE SYNCHRONOUS 
METASTATIC COLORECTAL CANCER
The resection of the primary tumor in mCRC has been favored as 
it prevents complications (e.g., obstruction, perforation, and 
bleeding) occurring with primary tumor growth and improves 
the quality of life of patients. In many cases, studies were not ran-
domized clinical studies, but were mostly retrospective analyses 
conducted at single institutes. Although many studies showed 
that actual resection of the primary tumor prolonged the median 
survival duration, making an objective comparison was difficult 
and a high likelihood of selection bias existed as the types of che-
motherapy regimen and introduction of chemotherapy after the 
resection were not consistent. 
Ruo et al. [10] analyzed the survival rate for patients with unre-
sectable asymptomatic stage IV colorectal cancer. Of the total 209 
patients, the first-line surgery group and the first-line chemother-
apy group included 82 and 127 patients, respectively. In the com-
parison of patients’ characteristics, right colon cancer was pre-
dominant in the first-line surgery group and a single metastatic 
lesion was predominant in the patients with liver metastasis only. 
When it comes to the survival duration, there was a statistical dif-
ference between the groups; the survival durations of the first-line 
surgery group and the first-line chemotherapy group were 16 
months and 9 months, respectively (P < 0.001). The extent of he-
patic metastasis was also an important prognosis factor in the 
multivariate analysis. 
Galizia et al. [7] analyzed 65 colorectal cancer patients with un-
resectable hepatic metastasis. The numbers of patients in the first-
line surgery group and the first-line chemotherapy group were 42 
and 23, respectively. Although there was no specific difference in 
patients’ characteristics, the initiation of chemotherapy in the 
first-line surgery group was 35 days, which was 8 days later com-
pared to that of the first-line chemotherapy group. However, there 
was a significant difference in survival duration between those 
groups; the survival durations of the first-line surgery group and 
the first-line chemotherapy group were 15.2 months and 12.3 
months, respectively (P = 0.003). In the multivariate analysis re-
garding the survival rate, resection of primary tumors and less 
than 50% hepatic metastasis were significant prognosis factors if 
the performance status was satisfactory. 
Kaufman et al. [18] investigated 185 stage IV colorectal cancer 
patients and found the survival duration in the first-line surgery 
group was 22 months, which was 3 months longer than that of the 
first-line chemotherapy group (P < 0.0001); further, the survival 
duration of the surgery plus chemotherapy group was 30 months, 
which was significantly longer than that of the group with chemo-
therapy only (15 months, P < 0.0004). Therefore, it was concluded 
that primary tumor resection was beneficial to improve the sur-
vival rate in the investigated cases of colorectal cancer.
In another study, Bajwa et al. [19] analyzed 67 colorectal cancer 
patients with unresectable hepatic metastasis. There were 32 and 
35 patients in the first-line surgery group and the first-line che-
motherapy group, respectively. The survival durations of the first-
line surgery group and the first-line chemotherapy group were 14 
months and 6 months, respectively, which were significantly dif-
ferent (P = 0.005). The occurrence of complications after the sur-
gery and the mortality rate were 25% and 3%, respectively. In the 
results of the prognosis factor analysis, surgical resection and pos-
itive responses to chemotherapy were favorable prognosis factors 
while proximal colon cancer and multiple primary cancers were 
unfavorable prognosis factors.  
Karoui et al. [20] performed a retrospective multi-institutional 
analysis of patients with unresectable stage IV colon cancer utiliz-
ing the data from 6 hospitals. The authors investigated the associ-
ation between the resection of the primary tumor and overall sur-
vival and only analyzed patients with favorable (Eastern Coopera-
tive Oncology Group [ECOG] performance status 0–1); further, 
recent targeted therapy drugs were included for the chemotherapy 
excluding rectal cancer. Of the total 208 patients, the first-line sur-
gery group included 85 patients while the first-line chemotherapy 
group included 123 patients. No difference in patients’ character-
istics was observed between the two groups whereas overall sur-
vival was significantly different; the overall survivals of the first-
line surgery group and the first-line chemotherapy were 30.7 and 
21.9 months, respectively, indicating a significant difference (P = 
0.031). According to the multivariate analysis, resection of pri-
mary tumors, cases where primary resection was available after 
first-line chemotherapy, well-differentiated tumors, cases with he-
patic metastasis only, and cases in which patients were introduced 
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to an anti-vascular endothelial growth factor (VEGF) agent were 
found to be prognosis factors and had a positive effect on the sur-
vival rate. The occurrence rate of complications related with pri-
mary tumors was 19% (n = 23): 21 patients with obstruction and 
2 patients with perforation. Of the 21 patients with obstruction, 8 
patients were treated with stent insertion while 13 patients were 
treated with a colectomy without stoma formation. Because anti-
VEGF agent has been reported to increase the risk of perforation 
[21], the two patients with perforation were not treated with anti-
VEGF agent, but were treated with resection of the primary tu-
mor along with stoma formation. Thus, the authors suggested that 
application of anti-VEGF agent followed by resection of the pri-
mary tumor would be beneficial if patients present with favorable 
physical conditions, well-differentiated tumors, and hepatic me-
tastases only even though there is a lack of evidence regarding the 
improvement of the survival rate in the first-line surgery group. 
Recently, Venderbosch et al. [22] and Ferrand et al. [23] re-
ported the results from a retrospective analysis of prospective, 
randomized clinical studies. Venderbosch et al. [22] retrospec-
tively analyzed the CAIRO (CApecitabine, IRinotecan, and Oxali-
platin) and the CAIRO2 studies, randomized phase III clinical 
studies in patients with mCRC. In the CAIRO study, the authors 
compared the treatment group with first-line capecitabine, sec-
ond-line irinotecan and third-line capecitabine plus oxaliplatin to 
the group with first-line capecitabine plus irinotecan and second-
line capecitabine plus oxaliplatin [24]. Of the total 399 patients, 
there were 258 patients in the first-line surgery group and 141 pa-
tients in the first-line chemotherapy group. In the analysis of pa-
tients’ characteristics, the first-line chemotherapy group showed 
more frequent abnormal lactate dehydrogenase (LDH), extrahe-
patic metastasis, and rectal and rectosigmoid colon tumors. The 
overall survivals and the progression free survivals (PFSs) in the 
first-line surgery group and the first-line chemotherapy group 
were 16.7 months and 11.4 months, and 6.7 month and 5.9 month, 
respectively, indicating that there were significant differences. In 
the multivariate analysis considering the patients’ characteristics, 
resection of primary tumors was shown to be a significant prog-
nosis factor. The frequencies of vomiting-related grade 3 to 4 tox-
icity were 11% and 5% (P = 0.053), and those of ileus-related 
grade 3 to 4 toxicity were 7% and 2% (P = 0.019) in the first-line 
surgery group and the first-line chemotherapy group, respectively. 
The CAIRO2 study investigated the cetuximab group in addi-
tion to the capecitabine, oxaliplatin, and bevacizumab treatment 
group [25]. A total of 448 patients were included: 289 and 159 pa-
tients in the first-line surgery group and the first-line chemother-
apy group, respectively. In the patients’ characteristics compari-
son, male patients were outnumbered in the first-line chemother-
apy group; further, abnormal LDH, poor performance status, and 
metastatic lesions, including liver metastases, were more fre-
quently shown in the first-line chemotherapy group. Overall sur-
vivals and PFSs were 20.7 months and 13.4 months, and 10.5 
months and 7.8 months, respectively, which were all significantly 
different. In the multivariate analysis considering the patients’ 
characteristics, resection of the primary tumor was an important 
prognosis factor in overall survival. Nausea (P = 0.004), vomiting 
(P = 0.043), ileus (P = 0.019), and fatigue-related grade 3 to 4 tox-
icity (P = 0.004) were all significantly higher in the first-line che-
motherapy group. Thus, considering the results in both the 
CAIRO and the CAIRO2 studies, resection of primary tumors 
was the major prognosis factor in regard to improved overall sur-
vival. 
The Fédération Francophone de Cancérologie Digestive (FFCD) 
9601 trial, which is a randomized phase-3 clinical study, com-
pared the efficacy of 5-FU infusion and Raltitrexed with three dif-
ferent schedules as a first-line chemotherapy for patients with 
mCRC [26]. Ferrand et al. [23] retrospectively analyzed 294 pa-
tients recruited from 39 hospitals, and 216 patients were found to 
be synchronous metastatic patients. One hundred fifty-six pa-
tients (72%) had undergone a resection of the primary tumor 
prior to the study initiation. A significant difference was shown in 
the locations of the primary tumors, indicating that 14% of pa-
tients in the first-line surgery group had a tumor in the rectum as 
opposed to 35% in the first-line chemotherapy group. Analyzing 
the survival rate, the PFSs and the overall survivals of the first-line 
surgery group and the first-line chemotherapy group were 5.1 
months and 2.9 months, and 16.3 months and 9.6 months, re-
spectively; both survival rates were higher in the first-line surgery 
group than in the first-line chemotherapy group. Resection of the 
primary tumors was the most significant prognosis factor in the 
multivariate analysis, as well. The percentage of hospitalization for 
surgery and obstruction was 7% in both groups. Thus, in the 
study, resection of primary tumors was shown to improve the 
survival rate for synchronous mCRC patients who were under 
first-line, single-agent chemotherapy. 
One of the major limitations of the study is that resection of pri-
mary tumors had already been determined prior to the study’s 
initiation. Thus, clear justifications for not resecting the primary 
tumors could not be found. To be specific, unresectable primary 
tumors, poor performance status of patients, cases in which sys-
temic chemotherapy should used due to the complications of 
metastatic lesions prior to the surgery, and symptoms related to 
the primary tumor could have been possible justifications. How-
ever, in the multivariate analysis, resection of primary tumors was 
found to be a significant prognosis factor in the CAIRO study, the 
CAIRO2 study, and the FFCD 9601 study. Furthermore, in these 
studies, the chemotherapy regimen did not include recent tar-
geted agents. Regardless, the survival duration was shown to be 
improved, as found in Venderbosch et al. [22]’s CAIRO/CAIRO2 
analysis. In summary, it was suggested that the improved survival 
duration was not associated with the types of chemotherapy regi-
mens. In Stillwell et al. [27]’s meta-analysis, it was expected that 
resection of primary tumors would prolong by approximately 6 
months the median survival duration. 
Anwar et al. [28] published a systematic review of 21 studies re-
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ported between 1980 and 2010. In this systematic review, the au-
thors compared the first-line surgery group and first-line chemo-
therapy group in mCRC. To evaluate the impact on the survival, 
the authors included asymptomatic patients. Patients undergoing 
non-resectional surgery such as bypass procedure or enterostomy 
were also included in the first line chemotherapy group. They 
concluded that resection of primary tumors may reduce obstruc-
tion, which requires emergency operation, and improve the sur-
vival rate. Further, delaying chemotherapy owing to the resection 
would not negatively affect the survival rate for patients. However, 
a major limitation of the study was that it was not based on a 
comparison of randomized clinical studies; in the multivariate 
prognosis-factor analysis, tumor burden and performance status 
were significant prognosis factors for the survival rate. The au-
thors concluded that in stage IV colorectal cancer patients, resec-
tion of primary tumors should be determined based on tumor 
burden or performance status rather than symptoms. 
Scheer et al. [29] made a comparison between the first-line sur-
gery group and first-line chemotherapy group in asymptomatic 
stage IV colorectal cancer patients. The primary objective was to 
investigate tumor-related complications in the first-line chemo-
therapy group, and the authors suggested performing chemother-
apy for asymptomatic cancer patients. However, in the study, the 
survival rate of the first-line surgery group was higher than that of 
the first-line chemotherapy group, which might be a possible lim-
itation of the study regarding biased selection of patients. 
Lastly, Stillwell et al. [27]’s meta-analysis was reviewed. In the 
study, the authors performed a meta-analysis of data from eight 
retrospective, single-institute studies that included both asymp-
tomatic and minimally-symptomatic unresectable colorectal can-
cer patients. Of the 1,062 patients, the first-line surgery group and 
the first-line chemotherapy group included 725 and 337 patients, 
respectively. The median survival durations of the first-line sur-
gery group and the first-line chemotherapy group were 14 to 23 
months and 6 to 22 months, respectively; the estimated survival 
advantage of the first-line surgery group was 6 months. The prog-
nosis factors related to the survival rate were tumor burden and 
performance status. The cases where radical resection was possi-
ble after the primary treatment for both the first-line surgery 
group and the first-line chemotherapy group were analyzed; 1.8% 
to 18.8% and 1.2% to 22% of the patients were available for the 
radical resection after the primary treatment in the first-line sur-
gery group and first-line chemotherapy group, respectively. There 
was no difference noted between the groups. In the first-line sur-
gery group, the complication rate after surgery was 23%; the most 
common complication was wound infection. The mortality was 
1.7%. When the frequency of intestinal complications was quanti-
tatively analyzed, the first-line chemotherapy group had a 7.3 
times higher risk than the first-line surgery group. 
The intestinal complication rate in the first-line chemotherapy 
group was 22.2%, and 18.3% of the patients required the surgery 
with complications required surgery. Obstruction was the most 
common complication. Obstruction was most common in the 
rectum (41.5%), followed by the left colon (34.1%) and the right 
colon (24.4%). The length of hospitalization of the first-line che-
motherapy group was 11 days, which was significantly shorter 
than that of the first-line surgery group (P = 0.003). In summary, 
the survival rate was shown to be improved in the group with re-
section of the primary tumor, and no convincing evidence was 
found for negative impacts of chemotherapy on tumor responses 
or survival even though the first-line surgery group showed a lon-
ger hospitalization and had delayed chemotherapy. In addition, 
the authors suggested that resection of primary tumors might 
prevent emergency surgery for such complications as it would re-
duce intestinal complications. 
Karoui et al. [20] pointed out that even though patients with ob-
struction had been treated with stent insertion, the chemotherapy 
would be delayed during the stent insertion and symptom devel-
opment. Further, minimally-invasive surgery, such as laparoscopic 
surgery, has been becoming more popular for stage IV colorectal 
cancer patients. Because it allows faster recovery with shorter hos-
pitalization compared to conventional laparotomy, laparoscopic 
surgery should be strongly considered for the patients’ sake [30]
(Tables 2 and 3). 
THE OPINION IN FAVOR OF FIRST-LINE 
CHEMOTHERAPY IN UNRESECTABLE 
SYNCHRONOUS METASTATIC COLORECTAL 
CANCER
Traditionally, 5-FU was the only chemotherapeutic agent that 
could be administered to patients with mCRC. The response rate 
was approximately 20%, and it was difficult to expect long-term 
survival for most unresectable colorectal cancer patients with liver 
metastases [31]. Chemotherapeutic agents, administration meth-
ods, and novel biological agents for the treatments of colorectal 
cancer with liver metastases allowed surgery to be performed 
even for initially unresectable metastatic lesions. The response 
rates of new cytotoxic chemotherapeutic agents such as oxalipla-
tin and irinotecan were improved by more than 50%, and more 
than 38% of the patients with unresectable lesions were able to 
have resections [32, 33].
The survival rate of patients with mCRC has rapidly increased 
since 1990 because of the development of chemotherapy and sur-
gery. The median survival duration of patients with stage IV 
colorectal cancer was 14.2 months in the 1990s, and it was in-
creased to 18.6 months in early 2000s and to even 30 months re-
cently. The five-year overall survival in stage IV patients was im-
proved from 9.1% in the 1990s to 19.2% in 2003. Such an im-
provement in the survival rate before 2004 was due to the increase 
in the number of resections performed, around 20% of the pa-
tients with metastatic colorectal cancer underwent resections, 
whereas the results after 2004 were mainly due to new chemo-
therapy regimens.
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A retrospective study was carried out based on SEER data and 
based on data on patients who received treatment for metastatic 
colorectal cancer at the MD Anderson Cancer Center and the 
Mayo Clinic in the US from 1990 to 2005 [34]. Of the 2,470 pa-
tients with mCRC, no significant difference was observed in the 
results between the Mayo Clinic (n = 856) and the MD Anderson 
Cancer Center (n = 1,614) (P = 0.58). Overall median survival 
durations were similar from 1990 to 1997, but the second half of 
the study period, the five-year overall survival duration was sig-
nificantly increased (14.2 months). Such improvements of the 
survival rate in those two institutes showed a pattern similar to 
that seen in the study done by SEER with 49,459 metastatic 
colorectal cancer patients from 1990 to 2005. The median survival 
duration was increased by 8–9 months until 2003 and then by 11 
months in 2004–2005. The five-year overall survival duration was 
also dramatically increased. This indicates that most of the pa-
tients with mCRC lived for a long period of time even though 
complete recovery was not possible. Practically, since 2005, more 
than 30% of the patients who were diagnosed with mCRC have 
survived for more than 5 years.
Moreover, a couple of studies found that the response rate, the 
survival rate, and the disease-free survival rate were improved in 
patients with stage IV colorectal cancer by utilizing bevacizumab, 
the monoclonal antibody against VEGF, a targeted therapy drug 
[35-37]. The median survival duration increased to 2 years be-
cause of the development of chemotherapy agents [38, 39]. In ad-
dition to the median survival duration, chemotherapy greatly re-
duced not only hepatic metastasis size but also the size of primary 
tumors. Both metastatic lesions and primary tumors showed re-
sponses with chemotherapy only. Furthermore, primary tumors 
have shown complete responses to new cytotoxic and targeted 
agents [40]. 
Poultsides et al. [41] investigated the complications caused by 
primary tumors when first-line chemotherapy was performed in 
233 stage IV colorectal cancer patients. Oxaliplatin- or irinotecan-
based triple-drug chemotherapy (fluorouracil, leucovorin) with 
or without bevacizumab was utilized as the chemotherapy regi-
men. Emergency surgery for obstruction and perforation due to 
primary tumors was required in 16 patients (7%). A total of 213 
patients (89%) did not require any surgical and nonsurgical treat-
ments for primary tumors. Another animal study reported that 
surgical resection altered the immune responses in patients, 
thereby facilitating the growth of tumors after surgery [42]. More-
over, a couple of recent studies reported that a resection of the 
primary tumor was not required in cases of intact primary tumors 
for stage IV colorectal cancer. According to those studies, surgical 
resection was necessary in less than 15% of the cases while the re-
maining 85% of the cases did not require a resection [41, 43-46]. 
Additionally, even though palliative resection of the primary tu-
mor was carried out for mCRC, complications related to the large 
intestine could occur later, and surgery should be applied in some 
cases [43, 47]. Based on these studies, the resection rate of pri-
mary tumors has decreased gradually [5]. 
The opinion in favor of first-line chemotherapy indicated that 
Table 2. Demographic data from selected studies
Investigator Resection
Chemotherapy 
after 
resection
Nonresection &
first-line 
chemotherapy
Right-sided colon primary
tumor
>25% Hepatic parenchymal 
metastases
Extrahepatic 
metastases
Resection Nonresection Resection Nonresection Resection Nonresection
Ruo et al. [10] 127 0 (0) 103a 58 (46) 29 (28) 40 (41) 29 (55) 56 (44) 61 (59)
Galizia et al. [7] 42 42 (100) 23 12 (29) 6 (26) 26 (62) 14 (61) NA NA
Kaufman et al. [18] 115 115 (100) 21 NA NA NA NA NA NA
Bajwa et al. [19] 32 32 (100) 35 14 (47) 10 (29) NA NA 0 (0) 0 (0)
Venderbosch et al. [22] 258 258 (100) 141 183 (71)b 78 (55)b NA NA 23 (9) 26 (19)
289 289 (100) 159 128 (51) 71 (48) NA NA 34 (12) 4 (3)
Karoui et al. [20] 85 84 (99) 123 30 (35) 37 (30) NA NA 34 (40) 47 (38)
Ferrand et al. [23] 216 156 (72) 60 52 (34) 10 (17) NA NA NA NA
Scoggins et al. [44] 66 0 (0) 23a 31 (47) 6 (26) 18 (32) 8 (40) 10 (15) 9 (39)
Tebbutt et al. [43] 280 280 (100) 82 188 (67)b 44 (54)b NA NA 56 (20)c 11 (13)c
Michel et al. [9] 31 30 (97) 23 28 (90)b 15 (65)b 11 (36)d 9 (39)d NA NA
Benoist et al. [12] 32 30 (94) 27 9 (28) 9 (33) 27 (84) 24 (89) 2 (6) 2 (7)
Seo et al. [52] 144 144 (100) 83 30 (21) 26 (31) 75 (52)d 50 (60)d NA NA
McCahill et al. [53] NA NA 86 NA NA NA NA NA NA
Values are presented as number (%).
NA, not available.
aIncluding chemoradiation. bColon. cPeritoneal/omental metastasis. dFive liver metastases or more.
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the use of systemic chemotherapy would be delayed when a resec-
tion had been performed and that, sometimes, chemotherapy 
would be unavailable due to the complications associated with 
surgery. Early use, as compared to later use, of palliative chemo-
therapy is advantageous for the quality of life and the overall sur-
vival [48]. Because the occurrences of the symptoms caused by 
primary tumors are not very high in most cases, it has been 
pointed out that surgical resection is unnecessary. In some cases, 
a hepatectomy is performed at first in colorectal cancer patients 
with hepatic metastasis because the incidence of complications is 
low in cases of asymptomatic colorectal cancer [49-51]. To date, 
however, such data have not been very reliable because there have 
been no prospective comparison studies with appropriate designs. 
Scoggins et al. [44] analyzed 89 stage IV colorectal cancer pa-
tients. The first-line surgery group for primary tumors and the 
first-line chemotherapy group contained 66 and 23 patients, re-
spectively. In the first-line surgery group, the incidence of compli-
cations after surgery was 30.3%, and the mortality rate was 4.6%. 
Wound infection and sepsis were the most common complica-
tions. Only 2 cases (8.7%) in the first-line chemotherapy group 
showed obstruction caused by the primary tumors. No significant 
difference was observed in survival duration between the first-
line surgery group (14.5 months) and the first-line chemotherapy 
group (16.6 months) (P = 0.59). 
Tebutt et al. [43] investigated the incidence of intestinal compli-
cations in 362 patients with unresectable colorectal cancer. Two 
hundred eighty patients and 82 patients were in the first-line sur-
gery group and the first-line chemotherapy group, respectively. 
Obstruction was exhibited in 37 patients in the first-line surgery 
group (13.2%) and in 11 patients in the first-line chemotherapy 
group (13.4%), but the difference was not significant. However, 14 
patients in the first-line surgery group (38%) required surgical 
treatments because of obstruction whereas 8 patients in the first-
line chemotherapy group (73%) requested surgical treatments. 
Peritonitis, fistula formation, and intestinal hemorrhage were ob-
served in 2.4%, 3.7%, and 3.7% of the patients in the first-line 
chemotherapy group, respectively. The median survival durations 
were 14 months and 8.2 months for the first-line surgery group 
and the first-line chemotherapy group, respectively, but the differ-
ence was not statistically significant. 
Table 3. Outcome data from selected studies
Investigator
Complications 
after resection
Mortality after 
resection
Complications after 
nonresection
Survival (mo) Chemotherapy 
regimen
Follow-up 
(mo)Resection Nonresection Significance
Ruo et al. [10] 26 (20.5) 2 (1.6) 30 (29) 16 9 <0.001 NA NA
Galizia et al. [7] 9 (21) 0 (0) 7 (30.4) 15.2 12.3 0.003 5-FU-based, oxaliplatin, 
  or irinotecan
21
Kaufman et al. [18] NA NA NA 22 15 NA NA NA
Bajwa et al. [19] 8 (25) 1 (3) NA 14 6 0.005 5-FU-based, oxaliplatin, 
  irinotecan
NA
Venderbosch et al. [22] NA NA NA 16.7 11.4 <0.001 Capecitabine, oxaliplatin,
  irinotecan
31.5
NA NA NA 20.7 13.4 <0.001 Capecitabine, oxaliplatin,
  bevacizumab, cetuximab
23
Karoui et al. [20] NA NA 23(19) 30.7 21.9 0.031 Oxaliplatin, irinotecan, 
  bevacizumab, cetuximab
19.7
Ferrand et al. [23] 12 (7)a NA 4 (7)a 16.3 9.5 <0.0001 5-FU-leucovorin, raltitrexed 33
Scoggins et al. [44] 20 (30.3) 3 (4.6) 3 (13) 14.5 16.6 NS NA NA
Tebbutt et al. [43] 37 (13.2)b NA 11 (13.4)b 14 8.2 NS 5-FU-based, other 30 (R), 19 (NR)
Michel et al. [9] NA 0 (0) 5 (21.7) 21 14 NS Oxaliplatin, irinotecan NA
Benoist et al. [12] 6 (19) 0 (0) 4 (14.8) 23 22 NS 5-FU-leucovorin, oxaliplatin,
  irinotecan, other
24
Seo et al. [52] 29 (20.2)c 0 (0) 17 (20.5)c 22 14 NS Fluoropyrimidine, oxaliplatin,
  irinotecan, bevacizumab,
  or cetuximab
49
McCahill et al. [53] NA NA 12 (14) NA 19.9 NA Oxaliplatin, Leucovorin, 5-FU, 
  bevacizumab
20.4
Values are presented as number (%).
NA, not available; 5-FU, 5-fluorouracil; R, resection; NR, nonresection; NS, not significant. 
aAdmission for surgery or bowel obstruction. bIntestinal obstruction. cIntestinal complication. 
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Michel et al. [9] analyzed a total of 44 patients with mCRC. There 
were 31 patients in the first-line surgery group and 23 patients in 
the first-line chemotherapy group. Rectal cancer was rarely ob-
served in the first-line surgery group, but more than at least three 
hepatic metastases was exhibited in many cases. The median sur-
vival durations were 21 months and 14 months for the first-line 
surgery group and the first-line chemotherapy group, respectively, 
but this difference was not significant (P = 0.718). In the first-line 
chemotherapy group, 21.7% of the patients required surgical treat-
ments due to obstruction. 
Benoist et al. [12] performed a case-matched study of 59 
colorectal cancer patients with unresectable hepatic metastasis. 
There were 27 patients in the first-line surgery group and 32 pa-
tients in the first-line chemotherapy group. The median survival 
durations were 22 months and 23 months for the first-line surgery 
group and the first-line chemotherapy group, respectively, but no 
statistical difference was indicated. Of the first-line surgery group, 
19% showed complications after the surgery while 14.8% of the 
first-line chemotherapy group showed complications associated 
with the primary tumors. A significant difference was observed in 
the lengths of hospitalization, 22 days for the first-line surgery 
group and 11 days for the first-line chemotherapy group.
Seo et al. [52] investigated 227 patients with unresectable stage 
IV colorectal cancer. A total of 144 and 83 patients were included 
in the first-line surgery group and the first-line chemotherapy 
group, respectively. Major intestinal complications, including ob-
struction, peritonitis, fistula formation, and bleeding, were exhib-
ited in 20.2% of the first-line surgery group and 20.5% of the first-
line chemotherapy group, but this difference was not significant. 
However, a significant difference was found in the initiation time 
of chemotherapy, which was 37 days for the first-line surgery 
group and 7 days for the first-line chemotherapy group (P < 
0.001). The median survival durations of the first-line surgery 
group and the first-line chemotherapy group were 22 months and 
14 months, respectively, but no statistically significant difference 
was indicated. In the multivariate analysis, high grade differentia-
tion and more than five hepatic metastatic lesions were unfavor-
able prognosis factors while the utilization of oxaliplatin was re-
lated to a favorable survival rate.  
Recently, the results of the National Surgical Adjuvant Breast 
and Bowel Project (NSABP) Trial C-10 were published [53]. This 
study was a phase-2 clinical trial to investigate the safety of non-
surgical treatment when unresectable stage IV colorectal cancer 
patients with asymptomatic primary tumors were treated using 
5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) che-
motherapy drugs with Bevacizumab. The patients in ECOG per-
formance status 0–1, excluding rectal cancer, participated in the 
project. The project was not focused to compare the first-line sur-
gery group and the first-line chemotherapy group regarding pri-
mary tumors. The main objective of the study was to analyze pa-
tients for whom surgery was needed due to major morbidity 
events, such as bleeding, perforation, obstruction, and fistula for-
mation, caused by primary tumors. The study was carried out 
with 86 patients in 29 hospitals. The median follow-up duration 
was 20.7 months, and major morbidity events were shown in 12 
patients (14%). Of those 12 patients, 10 underwent surgery owing 
to obstruction (8 cases), perforation (1 case), and abdominal pain 
(1 case); and the other 2 patients expired. Of the 10 patients who 
underwent surgery, 6 involved urgency while 4 did not; 1 patient 
(10%) died after the surgery. In chemotherapy-related cases, with 
a 19.9-month median survival duration, 4 patients expired. The 
cumulative incidence of major morbidity at the 24th month was 
16.4%; chemotherapy with mFOLFOX6 and bevacizumab was 
carried out in the remaining 83.6% without major complications 
due to the primary tumors. Therefore, the study suggested that 
the resection of asymptomatic primary tumors was not necessary 
prior to chemotherapy. Regarding the clinical problems when ad-
ministering bevacizumab, previous studies reported that 3.1% to 
5.1% moderate or severe bleeding occurred. Although perforation 
was not frequently encountered (approximately 1.5%), careful at-
tention was still required [5, 35, 36]. In the NSABP study, on the 
other hand, because only two patients showed perforation, ad-
ministration of bevacizumab was considered to be safe. 
Regarding the result of NSABP Trial C-10, Chang [54] pointed 
out that asymptomatic primary tumors were not clearly defined. 
It was reported that the late onset caused by the progression of the 
tumors or intestinal stenosis after first-line chemotherapy had not 
been well known. Temple et al. [6] pointed out that the mortality 
after primary tumor resection, 9%, was elevated by 26% when 
surgery was performed after chemotherapy. In a study by Poult-
sides et al. in 2009 [41], the mortality after emergency resection 
was also very high (12.5%). Therefore, the authors suggested that 
colonoscopy on a regular basis to diagnose in advance the com-
plications associated with the primary tumors would be useful in 
order to avoid emergency situation.
In 2008, a systematic review was carried out by Scheer et al. [29] 
based upon the data on 850 patients from 7 papers published 
from 1999 to 2006. When first-line chemotherapy was performed 
in unresectable stage IV colorectal cancer patients, obstruction 
caused by primary tumors and intestinal hemorrhage were ob-
served in 13.9% and 3% of the patients, respectively. On the other 
hand, when first-line surgery for primary tumors was carried out, 
complications were frequent, 18.8% to 47%, after the surgery. 
Thus, the researchers recommended implementing chemotherapy 
first. Furthermore, they mentioned that the patients who pos-
sessed asymptomatic primary tumors died due to metastasis and 
the progression of the carcinoma; on the other hand, it would be 
very rare to die because of the complications related to primary 
tumors [55].
Damjanov et al. [3] suggested that chemotherapy including new 
targeted therapy drugs increased response rates of metastatic le-
sions, as well as primary tumors [56]. Moreover, intestinal com-
plications, such as obstruction due to primary tumors and intesti-
nal hemorrhage, could be treated by using endoscopic stent inser-
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tion and hemostatic treatment. Therefore, the authors strongly 
recommended performing chemotherapy first, instead of resec-
tion, in patients having unresectable stage IV colorectal cancer 
with asymptomatic primary tumors. 
In 2012, the Cochrane collaboration analyzed 7 studies with a 
total of 1,086 patients, including 722 in the first-line surgery 
group and 364 in the first-line chemotherapy group [57]. It was 
reported that there was no difference in overall survival between 
those two groups was reported. Also, no sufficient reasons were 
found to support the conclusion that surgical resection reduced 
the complications associated with primary tumors. However, as 
the review paper was a retrospective, single-institute study, pro-
spective comparison studies are warranted in the future. Addi-
tionally, three ongoing studies were introduced: 
1) Chemotherapy with or without surgery in treating patients 
with mCRC that cannot be removed by surgery (ClinicalTrials.
gov study no. NCT01086618): 
Purpose: To determine whether overall survival is improved in 
patients with asymptomatic, unresectable metastatic colorectal 
cancer treated with chemotherapy alone versus surgery followed 
by chemotherapy.
2) The SUPER Study: A randomized phase III multicenter trial 
evaluating the role of palliative surgical resection of the primary 
tumors in patients with mCRC (ACTRN12609000680268):
Purpose: To determine whether surgical resection of the pri-
mary tumors in patients with stage IV colorectal cancer decreases 
intestinal complications and improves overall survival and quality 
of life.
3) Resection of the primary tumors versus no resection prior to 
systemic therapy in patients with colon cancer and synchronous 
unresectable metastases (Union for International Cancer Control 
stage IV): a randomized controlled multicenter trial (IS-
RCTN30964555): 
Purpose: To evaluate the efficacy of primary tumor resection 
prior to systemic chemotherapy to prolong survival in patients 
with newly diagnosed colon cancer who are not amenable to cu-
rative therapy [58].
CONCLUSION
Disagreements exist as to whether the appropriate primary treat-
ment for unresectable stage IV colorectal cancer patients with as-
ymptomatic primary tumors is surgical resection or chemother-
apy. Prospective comparison studies only focusing on first-line 
treatment modalities have not been performed yet; thus, future 
clinical studies with objectives regarding survival duration and 
quality of life should be implemented as soon as possible. In addi-
tion to clinical studies, multidisciplinary team approaches would 
be helpful in choosing the appropriate therapy. Regardless of 
symptoms, the performance status and the tumor burden should 
be considered as well. When performing surgical resection, mini-
mally invasive approaches, such as laparoscopic surgery, should 
be considered for the patients’ sake.
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